{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:37:03Z","timestamp":1783478223703,"version":"3.55.0"},"reference-count":46,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2025,7,3]]},"DOI":"10.1080\/17425255.2025.2507404","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T15:54:12Z","timestamp":1747324452000},"page":"789-800","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Lazertinib: a novel EGFR-TKI therapy for non-small cell lung cancer"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3427-960X","authenticated-orcid":false,"given":"Dhairavi","family":"Shah","sequence":"first","affiliation":[{"name":"Kean University","place":["Union, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3058-2820","authenticated-orcid":false,"given":"Dhaara","family":"Shah","sequence":"additional","affiliation":[{"name":"Kean University","place":["Union, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy","family":"Ndandji","sequence":"additional","affiliation":[{"name":"Kean University","place":["Union, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9411-2091","authenticated-orcid":false,"given":"Supratik","family":"Kar","sequence":"additional","affiliation":[{"name":"Kean University","place":["Union, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2016.06.07"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature25183"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194562"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01533-x"},{"key":"e_1_3_5_7_1","unstructured":"FDA. FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer. FDA. 2024 Aug 20. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer"},{"key":"e_1_3_5_8_1","unstructured":"Janssen Scientific Affairs. Lazcluze\u2122 (lazertinib). Janssen Science. 2024 Aug 20. Available from: https:\/\/www.janssenscience.com\/products\/lazcluze\/medical-content\/lazcluze-dosage-and-administration"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00551-9"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.013"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.20268"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-4-303"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-7-461"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0111-6"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1028-x"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0533-4"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01588-w"},{"key":"e_1_3_5_18_1","unstructured":"Biopharma A. ArriVent receives FDA breakthrough therapy designation for furmonertinib for first-line treatment of advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. ArriVent Biopharma. 2023 Oct 30. Available from: https:\/\/ir.arrivent.com\/news-releases\/news-release-details\/arrivent-receives-fda-breakthrough-therapy-designation"},{"key":"e_1_3_5_19_1","first-page":"119","article-title":"Portrazza (Necitumumab), an IgG1 monoclonal antibody, FDA approved for advanced squamous non-small-cell lung cancer","volume":"9","author":"Fala L","year":"2016","unstructured":"Fala L. Portrazza (Necitumumab), an IgG1 monoclonal antibody, FDA approved for advanced squamous non-small-cell lung cancer. Am Health Drug Benefits. 2016;9(Spec Feature):119\u2013122.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_5_20_1","unstructured":"Janssen Global Services. Lazcluze\u2122 prescribing information. Johnson & johnson innovative medicine. Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/LAZCLUZE-pi.pdf"},{"key":"e_1_3_5_21_1","unstructured":"Thomson RJ Moshirfar M Ronquillo Y. Tyrosine kinase inhibitors. StatPearls publishing. 2023 Jul 18. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563322\/"},{"key":"e_1_3_5_22_1","unstructured":"Oh S-H Khoo J-H Lim J-C et al. WO2019022486 - novel intermediates useful for the synthesis of aminopyrimidine derivatives process for preparing the same and process for preparing aminopyrimidine derivatives using the same. World Intellectual Property Organization; 2018. Available from: https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2019022486"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5270"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2022.63.9.799"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7290105"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00949-4"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00828-5"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.06.01"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2906"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.11.004"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0071"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2018.10.06"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00515"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0399"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30504-2"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.028"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.025"},{"key":"e_1_3_5_38_1","unstructured":"National Library of Medicine (U.S.). Clinical trial of YH25448 (lazertinib) as the first-line treatment in patients with EGFR mutation positive locally advanced or metastatic NSCLC (LASER301). Identifier NCT04248829. National Library of Medicine; 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04248829"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2024.107484"},{"key":"e_1_3_5_40_1","unstructured":"A study of Amivantamab and lazertinib in combination with platinum-based chemotherapy compared with platinum-based chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-Small cell lung cancer after Osimertinib failure (MARIPOSA-2). Available from: https:\/\/clinicaltrials.gov\/study\/NCT04988295"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14663"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100224"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107509"},{"key":"e_1_3_5_44_1","unstructured":"Janssen Scientific Affairs. Lazcluze\u2122 (lazertinib). Janssen Science. 2024 Nov 18. Available from: https:\/\/www.janssenscience.com\/products\/lazcluze\/medical-content\/lazcluze-drug-interactions"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.02.006"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061567"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01356"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102824"}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2025.2507404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:52:26Z","timestamp":1751367146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2025.2507404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,3]]}},"alternative-id":["10.1080\/17425255.2025.2507404"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2025.2507404","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}